NEW YORK (GenomeWeb News) — The US Food and Drug Administration yesterday said it has cleared Agendia’s MammaPrint diagnostic for breast cancer recurrence.
 
The test is the first in vitro diagnostic multivariate index assay device approved by the agency since it released a draft guidance describing such products last year.
 
As GenomeWeb News reported last fall, IVDMIAs use mathematical formulas to interpret gene and protein data to guide medical decision-making, according to the draft guidance, which can be read here.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.